TianYu Pharma (300702.SZ) Forecasts H1 Profit Surge: Net Profit Expected at 1.3B-1.8B Yuan, Up 144.29%-238.25% YoY

Stock Track07-15

TianYu Stock (300702.SZ) has released an upbeat preliminary earnings forecast for the first half of 2025. The pharmaceutical company anticipates net profit attributable to shareholders will reach 1.3 billion to 1.8 billion yuan, marking a remarkable year-on-year increase of 144.29% to 238.25%. Excluding non-recurring gains and losses, adjusted net profit is projected between 1.21 billion and 1.71 billion yuan, representing growth of 92.79% to 172.45% compared to the same period last year.

This substantial performance improvement stems from strategic operational enhancements implemented during the reporting period. Through optimizing product portfolios, expanding market presence, and strengthening cost-control measures, TianYu Pharma successfully boosted revenue and gross profit margins across multiple business segments. Key growth drivers included non-sartan active pharmaceutical ingredients (APIs) and intermediates, contract development and manufacturing organization (CDMO) services, and finished dosage form businesses. The company's focused execution transformed operational efficiencies into tangible financial gains, positioning it for sustained profitability momentum.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment